Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $88
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $88
Oppenheimer維持對corbus pharmaceuticals的優異評級,將目標股價上調至88美元。
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $80 to $88.
Oppenheimer分析師Jeff Jones維持對corbus pharmaceuticals(納斯達克:CRBP)的推薦並將目標價從80美元提高至88美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。